GridAI Technologies (GRDX) Receivables (2015 - 2025)

GridAI Technologies' (GRDX) quarterly Receivables came in at $1.3 million in Q4 2025, up 3471.69% on a QoQ basis from $37490.0 in Q3 2025.

GridAI Technologies (GRDX) Receivables (2015 - 2025) Analysis & Trends

GridAI Technologies (GRDX) has 10 years of Receivables data on file, last reported at $1.3 million in Q4 2025.

Quarterly Receivables changed N/A year-over-year to $1.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.3 million (changed N/A YoY) and the FY2025 annual result came in at $1.3 million, changed N/A from the prior year.
Receivables grew to $1.3 million in Q4 2025, from $37490.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $1.3 million in Q4 2025 to a low of -$53014.0 in Q1 2023.
A 4-year average of $295086.1 and a median of $84456.5 in 2022 frame the typical range for Receivables.
Annual changes were most pronounced in 2021 — Receivables soared 143.0% — and 2023, when it plunged 194.48%.
Tracing GRDX's Receivables over 4 years: stood at $560690.0 in 2021, then tumbled by 101.06% to -$5956.0 in 2022, then plunged by 790.09% to -$53014.0 in 2023, then soared by 2625.8% to $1.3 million in 2025.
The last three Receivables figures came in at $1.3 million (Q4 2025), $37490.0 (Q3 2025), and -$53014.0 (Q1 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Vertex Pharmaceuticals	138.90 Bn	131.05 Bn	2.84 Bn	2.13 Bn
2	Regeneron Pharmaceuticals	86.10 Bn	78.11 Bn	3.93 Bn	6.57 Bn
3	Argenx Se	65.56 Bn	60.37 Bn	1.37 Bn	1.93 Bn
4	Moderna	55.82 Bn	50.68 Bn	52.00 Mn	160.00 Mn
5	BeOne Medicines	42.14 Bn	37.04 Bn	1.53 Bn	1.06 Bn
6	Alnylam Pharmaceuticals	31.67 Bn	28.36 Bn	992.69 Mn	912.74 Mn
7	BioNTech SE	27.74 Bn	9.35 Bn	668.28 Mn	1.09 Bn
8	Insmed	27.53 Bn	26.37 Bn	358.27 Mn	215.33 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	-
10	GridAI Technologies	5.67 Mn	5.67 Mn	-	1.34 Mn

Download Data